Scarica l'app Stockscreener
143.92
0.80%
1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$142.73
Aprire:
$143.86
Volume 24 ore:
153.98K
Relative Volume:
0.18
Capitalizzazione di mercato:
$14.27B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
48.79
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+0.19%
1M Prestazione:
+8.06%
6M Prestazione:
+31.15%
1 anno Prestazione:
+20.04%
Intervallo 1D:
$143.34
$144.81
Intervallo di 1 settimana:
$139.25
$144.81
Portata 52W:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Confronta NBIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.87 | 14.16B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
147.43 | 65.12B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.66B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.245 | 42.03B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.41 | 21.08B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
406.38 | 18.26B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
5,541 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Financiere des Professionnels Fonds d investissement inc. - MarketBeat
Market Review: Should I trade or invest in Neurocrine Biosciences IncWeekly Trade Review & Reliable Momentum Entry Alerts - خودرو بانک
Aug Spikes: Does Neurocrine Biosciences Inc have pricing powerMarket Weekly Review & Risk Controlled Stock Pick Alerts - خودرو بانک
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences’ SWOT analysis: stock outlook amid pipeline progress, IRA challenges - Investing.com
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Voya Investment Management LLC - MarketBeat
Fed Watch: Why is Neurocrine Biosciences Inc stock going upJuly 2025 Highlights & Reliable Volume Spike Alerts - خودرو بانک
Woodline Partners LP Buys Shares of 132,892 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine to present new phase 2 data for depression treatment - Investing.com India
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 - WV News
First-in-Class AMPA-PAM Depression Treatment: Neurocrine's Osavampator Phase 2 Results at Major Conference - Stock Titan
What Does Wall Street Think About Neurocrine Biosciences (NBIX)? - uk.finance.yahoo.com
Moving Averages: Is Neurocrine Biosciences Inc stock forming a triangle patternQuarterly Profit Review & Free High Accuracy Swing Entry Alerts - خودرو بانک
Juncture Wealth Strategies LLC Sells 2,766 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Volatility Watch: How cyclical is Neurocrine Biosciences Incs revenue streamWeekly Loss Report & Daily Risk Controlled Trade Plans - خودرو بانک
City Center Advisors LLC Buys New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Hawaiian Bank Trims Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Swedbank AB Has $47.52 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Performance Recap: What are Neurocrine Biosciences Incs growth leversWeekly Trade Analysis & Breakout Confirmation Trade Signals - خودرو بانک
Intech Investment Management LLC Has $3.96 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
United Services Automobile Association Buys Shares of 6,547 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Integrated Wealth Concepts LLC Buys 4,526 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Plato Investment Management Ltd Has $255,000 Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Teza Capital Management LLC Has $587,000 Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Amundi Sells 30,673 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Jacobs Levy Equity Management Inc. - MarketBeat
Great Lakes Advisors LLC Has $3.54 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Vident Advisory LLC Invests $202,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Update - MarketBeat
Parkman Healthcare Partners LLC Buys 52,655 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Getting In Cheap On Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Might Be Difficult - 富途牛牛
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Alyeska Investment Group L.P. - MarketBeat
EFG Asset Management North America Corp. Has $1.12 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Baird Financial Group Inc. Buys 3,103 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Federation des caisses Desjardins du Quebec Lowers Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Fibonacci Support Holding Strong in Neurocrine Biosciences Inc.July 2025 Trends & Weekly Chart Analysis and Guides - beatles.ru
Palo Alto Investors LP Invests $1.48 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc. recovery potential after sell offJuly 2025 Momentum & Community Consensus Picks - Newser
Tick level data insight on Neurocrine Biosciences Inc. volatilityLong Setup & Entry Point Confirmation Signals - Newser
Braidwell LP Increases Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is Neurocrine Biosciences Inc. benefiting from interest rate changesEarnings Overview Summary & Low Risk Entry Point Tips - خودرو بانک
Can Neurocrine Biosciences Inc. generate free cash flowJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - خودرو بانک
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Macro Moves & Safe Entry Momentum Tips - Newser
Neurocrine Biosciences: RBC Capital maintains Outperform, raises PT to $149. - AInvest
Neurocrine Bio. stock price target raised to $149 by RBC Capital - Investing.com
RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating - MarketScreener
Armistice Capital LLC Acquires 108,190 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Summary & Reliable Intraday Trade Alerts - Newser
Will Neurocrine Biosciences Inc. benefit from current market trendsMarket Growth Review & Weekly Consistent Profit Watchlists - خودرو بانک
Will Neurocrine Biosciences Inc. price bounce be sustainable2025 Key Lessons & Long-Term Capital Growth Strategies - Newser
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
0.10%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):